IS6310A - Kínasólínafleiður til lækninga - Google Patents

Kínasólínafleiður til lækninga

Info

Publication number
IS6310A
IS6310A IS6310A IS6310A IS6310A IS 6310 A IS6310 A IS 6310A IS 6310 A IS6310 A IS 6310A IS 6310 A IS6310 A IS 6310A IS 6310 A IS6310 A IS 6310A
Authority
IS
Iceland
Prior art keywords
quinazoline derivatives
medicinal purposes
medicinal
purposes
quinazoline
Prior art date
Application number
IS6310A
Other languages
English (en)
Inventor
Austen Mortlock Andrew
John Keen Nicholas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6310A publication Critical patent/IS6310A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS6310A 1999-09-21 2002-03-19 Kínasólínafleiður til lækninga IS6310A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922171.5A GB9922171D0 (en) 1999-09-21 1999-09-21 Chemical compounds
PCT/GB2000/003593 WO2001021597A1 (en) 1999-09-21 2000-09-19 Therapeutic quinazoline derivatives

Publications (1)

Publication Number Publication Date
IS6310A true IS6310A (is) 2002-03-19

Family

ID=10861217

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6310A IS6310A (is) 1999-09-21 2002-03-19 Kínasólínafleiður til lækninga

Country Status (24)

Country Link
US (1) US7235559B1 (is)
EP (1) EP1218355A1 (is)
JP (1) JP2003509500A (is)
KR (1) KR20020030123A (is)
CN (1) CN1391563A (is)
AR (1) AR025735A1 (is)
AU (1) AU762697B2 (is)
BG (1) BG106526A (is)
BR (1) BR0014137A (is)
CA (1) CA2384296A1 (is)
CO (1) CO5200783A1 (is)
CZ (1) CZ20021008A3 (is)
EE (1) EE200200118A (is)
GB (1) GB9922171D0 (is)
HK (1) HK1046685A1 (is)
HU (1) HUP0300205A3 (is)
IL (1) IL148496A0 (is)
IS (1) IS6310A (is)
NO (1) NO20021400L (is)
PL (1) PL354870A1 (is)
SK (1) SK3872002A3 (is)
TR (1) TR200200717T2 (is)
WO (1) WO2001021597A1 (is)
ZA (1) ZA200202232B (is)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200715A (et) * 2000-06-28 2004-08-16 Astrazeneca Ab Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
JP2002293773A (ja) * 2001-03-30 2002-10-09 Sumika Fine Chemicals Co Ltd キナゾリン誘導体の製造方法
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
WO2003035602A1 (en) * 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
ES2333702T3 (es) 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
RS63204A (sr) 2002-01-17 2006-10-27 Neurogen Corporation Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
AU2003257666A1 (en) * 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
NZ539408A (en) 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
CA2529611C (en) 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7238679B2 (en) * 2002-12-23 2007-07-03 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
AU2003292435A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
WO2004056801A1 (en) * 2002-12-23 2004-07-08 Astrazeneca Ab Quinazoline derivatives
PT1847539E (pt) 2002-12-24 2009-10-06 Astrazeneca Ab Derivados de quinazolina
US7407946B2 (en) 2002-12-24 2008-08-05 Astrazeneca Ab Quinazoline compounds
WO2004058782A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab Therapeutic quinazoline derivatives
WO2004094410A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Chemical compounds
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
WO2004108707A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyridazinil quinazoline derivatives for use in the treatment of tumours
WO2004108711A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
WO2004108710A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab 4-pyrimidinyl quinazoline derivatives for use in the treatment of tumours
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
KR101028952B1 (ko) * 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
ES2344007T3 (es) * 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005042498A2 (en) * 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
BRPI0510963A (pt) 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
WO2005111024A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
ES2319462T3 (es) * 2005-03-28 2009-05-07 Bristol-Myers Squibb Company Inhibidores competitivos de atp cinasas.
AU2006233537A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
EP1994024A2 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
MX2009010517A (es) 2007-04-05 2009-10-19 Amgen Inc Moduladores de cinasa aurora y metodos de uso.
CN101215274B (zh) * 2007-12-27 2011-05-04 上海北卡医药技术有限公司 N取代吗啉类有机化合物的制备工艺
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
WO2009117157A1 (en) 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
KR20110133048A (ko) * 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
CN103304489B (zh) * 2012-03-16 2015-03-11 中国农业科学院兰州畜牧与兽药研究所 嘧啶苯甲酰胺类化合物及其制备和应用
DK3046584T3 (en) 2013-09-16 2017-10-02 Astrazeneca Ab THERAPEUTIC POLYMER NANOPARTICLES AND PROCEDURES FOR PREPARING AND USING THEREOF
HUE050761T2 (hu) 2014-01-01 2021-01-28 Medivation Tech Llc Vegyületek és alkalmazási eljárások
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
EP3184507A1 (en) * 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Preparation of phenyl compounds
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
EA039417B1 (ru) 2017-08-07 2022-01-25 Родин Терапеутикс, Инк. Бициклические ингибиторы гистондеацетилазы
US20220389026A1 (en) * 2019-08-20 2022-12-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compound used as cdc7 inhibitor
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
JP2002539262A (ja) * 1999-03-19 2002-11-19 パーカー ヒューズ インスティテュート キナゾリン化合物製剤および治療におけるその使用

Also Published As

Publication number Publication date
HK1046685A1 (zh) 2003-01-24
HUP0300205A2 (en) 2003-05-28
ZA200202232B (en) 2003-08-27
US7235559B1 (en) 2007-06-26
TR200200717T2 (tr) 2002-06-21
KR20020030123A (ko) 2002-04-22
AU7301900A (en) 2001-04-24
HUP0300205A3 (en) 2003-08-28
BG106526A (en) 2002-10-31
BR0014137A (pt) 2002-05-21
AR025735A1 (es) 2002-12-11
EE200200118A (et) 2003-04-15
CZ20021008A3 (cs) 2002-06-12
CO5200783A1 (es) 2002-09-27
NO20021400L (no) 2002-05-06
PL354870A1 (en) 2004-03-08
AU762697B2 (en) 2003-07-03
NO20021400D0 (no) 2002-03-20
EP1218355A1 (en) 2002-07-03
GB9922171D0 (en) 1999-11-17
IL148496A0 (en) 2002-09-12
WO2001021597A1 (en) 2001-03-29
CN1391563A (zh) 2003-01-15
SK3872002A3 (en) 2002-12-03
CA2384296A1 (en) 2001-03-29
JP2003509500A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
IS6310A (is) Kínasólínafleiður til lækninga
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
DE60039206D1 (de) Neue Quinazolin-Derivate
NO20015175L (no) Farmasöytisk sammensetning
EE200300071A (et) Kinasoliini derivaadid
NO20000885L (no) 4-Fenyl-pyridin-derivater
EP1214333A4 (en) SOLUBLE STABILIZED GLYCOPROTEIN TRIMERS
DE60009747D1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
DK1275397T3 (da) Lægemiddel til lokal anvendelse
PT1210085E (pt) Solucoes farmaceuticas de levosimendano
ATE257148T1 (de) Propargyletherderivate
NO20022606D0 (no) Farmasöytiske kombinasjoner
ATE273272T1 (de) Mevinolinderivate
ATE374747T1 (de) Monofluoralkylderivate
NO20014926D0 (no) Farmasöytiske forbindelser
ATE293592T1 (de) Resorcinderivate
DK1218340T3 (da) 4-hydroxybiphenylhydrazid-derivater
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
AR025867A1 (es) Formulacion portasdora farmaceutica
FI4488U1 (fi) Farmaseuttinen koostumus
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
NO20016430L (no) Farmasöytisk kompleks
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate